{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:01:07Z","timestamp":1790694067130,"version":"4.1.0"},"reference-count":43,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"St. Antonius Research Fund","award":["21.07"],"award-info":[{"award-number":["21.07"]}]},{"DOI":"10.13039\/501100014780","name":"Longfonds","doi-asserted-by":"publisher","award":["5.1.19.035"],"award-info":[{"award-number":["5.1.19.035"]}],"id":[{"id":"10.13039\/501100014780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,9,19]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>\u223c30% of patients with sarcoidosis, a systemic granulomatous disease of unknown cause, need treatment to alleviate symptoms or prevent organ damage. Prednisone and methotrexate (MTX) are the most commonly used drugs; however, success of treatment varies from patient to patient. In this study, we search for biomarkers and pathways that predict response to treatment with prednisone or MTX in extracellular vesicles (EVs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A targeted proteomics approach (OLINK Bioscience) was used in which 92 proteins were measured in two baseline EV fractions in 32 patients treated for pulmonary sarcoidosis (eight responders and eight non-responders each for prednisone and MTX). The top three proteins were replicated in 62 prednisone- and 76 MTX-treated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 11 differentially expressed proteins (DEPs) between responders and non-responders to prednisone treatment, and 16 DEPs for patients treated with MTX. Reactome pathway analysis showed DEPs in prednisone to be involved in nuclear factor kappa B and interleukin signalling pathways. The DEPs in MTX were involved in transduction of GPI-anchored proteins and MAPK signalling pathway. CHI3L1 for prednisone and CPA1 for MTX were replicated as significant predictors of response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study is the first to show that in pulmonary sarcoidosis the response to treatment with prednisone or MTX can be predicted at baseline by different EV proteins active in different pathways. Using these markers and associated pathways to identify patients with a high probability of response to therapy will aid personalised treatment choice and improve treatment outcome.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00672-2024","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T16:55:21Z","timestamp":1730998521000},"page":"00672-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeted proteomics in extracellular vesicles identifies biomarkers predictive for therapeutic response in sarcoidosis"],"prefix":"10.1183","volume":"11","author":[{"given":"Raisa","family":"Kraaijvanger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Janssen Bon\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Paspali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.V.","family":"de Kleijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coline H.M.","family":"van Moorsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"2025030303501271000_11.2.00672-2024.1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/14799731211031935","article-title":"Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population","volume":"18","author":"Kahlmann","year":"2021","journal-title":"Chron Respir Dis"},{"key":"2025030303501271000_11.2.00672-2024.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020"},{"key":"2025030303501271000_11.2.00672-2024.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00105805"},{"key":"2025030303501271000_11.2.00672-2024.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201210-1853PP"},{"key":"2025030303501271000_11.2.00672-2024.5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00074905"},{"key":"2025030303501271000_11.2.00672-2024.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-016-2694-x"},{"key":"2025030303501271000_11.2.00672-2024.7","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.06314"},{"key":"2025030303501271000_11.2.00672-2024.8","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0146-2019"},{"key":"2025030303501271000_11.2.00672-2024.9","first-page":"S5","article-title":"Mechanisms of action of methotrexate","volume":"71","author":"Chan","year":"2013","journal-title":"Bull Hosp Joint Dis"},{"key":"2025030303501271000_11.2.00672-2024.10","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.3390\/ijms20205023","article-title":"Methotrexate an old drug with new tricks","volume":"20","author":"Bedoui","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025030303501271000_11.2.00672-2024.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.22640"},{"key":"2025030303501271000_11.2.00672-2024.12","first-page":"907","article-title":"Polyglutamation of methotrexate","volume":"76","author":"Chabner","year":"1985","journal-title":"Perspectives (Montclair)"},{"key":"2025030303501271000_11.2.00672-2024.13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00408-023-00656-0","article-title":"Methotrexate polyglutamate concentrations as a possible predictive marker for effectiveness of methotrexate therapy in patients with sarcoidosis: a pilot study","volume":"201","author":"Janssen Bon\u00e1s","year":"2023","journal-title":"Lung"},{"key":"2025030303501271000_11.2.00672-2024.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.5.502"},{"key":"2025030303501271000_11.2.00672-2024.15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MCP.0000000000000306","article-title":"Biomarkers in sarcoidosis: the contribution of system biology","volume":"22","author":"Carleo","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"2025030303501271000_11.2.00672-2024.16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12890-020-01290-9","article-title":"Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study","volume":"20","author":"Kahlmann","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2025030303501271000_11.2.00672-2024.17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/intimm\/dxac009","article-title":"CD14 and LBP as novel biomarkers for sarcoidosis by proteomics of extracellular vesicles","volume":"34","author":"Futami","year":"2022","journal-title":"Int Immunol"},{"key":"2025030303501271000_11.2.00672-2024.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.07.004"},{"key":"2025030303501271000_11.2.00672-2024.19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fcvm.2018.00113","article-title":"Extracellular vesicles as biomarkers in cardiovascular disease: chances and risks","volume":"5","author":"Dickhout","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"2025030303501271000_11.2.00672-2024.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00763-8"},{"key":"2025030303501271000_11.2.00672-2024.21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-024-02809-y","article-title":"Decreased serpin C1 in extracellular vesicles predicts response to methotrexate treatment in patients with pulmonary sarcoidosis","volume":"25","author":"Kraaijvanger","year":"2024","journal-title":"Respir Res"},{"key":"2025030303501271000_11.2.00672-2024.22","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14d02.x"},{"key":"2025030303501271000_11.2.00672-2024.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00198-2023"},{"key":"2025030303501271000_11.2.00672-2024.24","first-page":"86","article-title":"A composite score to assess treatment response in pulmonary sarcoidosis: the sarcoidosis treatment score (STS)","volume":"36","author":"Baughman","year":"2019","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"2025030303501271000_11.2.00672-2024.25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12890-017-0447-x","article-title":"Lymphangioleiomyomatosis, multifocal micronodular pneumocyte hyperplasia, and sarcoidosis: more pathological findings in the same chest CT, or a single pathological pathway?","volume":"17","author":"Di Marco","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2025030303501271000_11.2.00672-2024.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201005-0792OC"},{"key":"2025030303501271000_11.2.00672-2024.27","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00125404"},{"key":"2025030303501271000_11.2.00672-2024.28","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1790139"},{"key":"2025030303501271000_11.2.00672-2024.29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201827"},{"key":"2025030303501271000_11.2.00672-2024.30","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.3109\/10428194.2014.1001984","article-title":"Circulating tumor necrosis factor-\u03b1 and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma","volume":"56","author":"El-Galaly","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2025030303501271000_11.2.00672-2024.31","first-page":"3749","article-title":"YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transition","volume":"9","author":"Hao","year":"2017","journal-title":"Am J Transl Res"},{"key":"2025030303501271000_11.2.00672-2024.32","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/15384101.2020.1750811","article-title":"YKL-40 mediates airway remodeling in asthma via activating FAK and MAPK signaling pathway","volume":"19","author":"Sun","year":"2020","journal-title":"Cell Cycle"},{"key":"2025030303501271000_11.2.00672-2024.33","doi-asserted-by":"publisher","DOI":"10.1080\/10408360802334743"},{"key":"2025030303501271000_11.2.00672-2024.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.12.006"},{"key":"2025030303501271000_11.2.00672-2024.35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/biom8030084","article-title":"YKL-40, soluble IL-2 receptor, angiotensin converting enzyme and C-reactive protein: comparison of markers of sarcoidosis activity","volume":"8","author":"Uysal","year":"2018","journal-title":"Biomolecules"},{"key":"2025030303501271000_11.2.00672-2024.36","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.3.1174-1180.1998"},{"key":"2025030303501271000_11.2.00672-2024.37","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(94)90043-4"},{"key":"2025030303501271000_11.2.00672-2024.38","doi-asserted-by":"publisher","DOI":"10.1186\/cc8850"},{"key":"2025030303501271000_11.2.00672-2024.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2004.01.010"},{"key":"2025030303501271000_11.2.00672-2024.40","doi-asserted-by":"crossref","first-page":"776879","DOI":"10.3389\/fimmu.2021.776879","article-title":"The macrophage reprogramming ability of antifolates reveals soluble CD14 as a potential biomarker for methotrexate response in rheumatoid arthritis","volume":"12","author":"Fuentelsaz-Romero","year":"2021","journal-title":"Front Immunol"},{"key":"2025030303501271000_11.2.00672-2024.41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/PAS.0000000000001817","article-title":"Carboxypeptidase A1 (CPA1) immunohistochemistry is highly sensitive and specific for acinar cell carcinoma (ACC) of the pancreas","volume":"46","author":"Uhlig","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"2025030303501271000_11.2.00672-2024.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59121-0"},{"key":"2025030303501271000_11.2.00672-2024.43","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.25.15804"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00672-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:53:02Z","timestamp":1741002782000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00672-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1183\/23120541.00672-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00672-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]}}}